Cargando…

A Specific Reduction in Aβ(1−42) vs. a Universal Loss of Aβ Peptides in CSF Differentiates Alzheimer's Disease From Meningitis and Multiple Sclerosis

A reduced concentration of Aβ(1−42) in CSF is one of the established biomarkers of Alzheimer's disease. Reduced CSF concentrations of Aβ(1−42) have also been shown in multiple sclerosis, viral encephalitis and bacterial meningitis. As neuroinflammation is one of the neuropathological hallmarks...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spitzer, Philipp, Lang, Roland, Oberstein, Timo J., Lewczuk, Piotr, Ermann, Natalia, Huttner, Hagen B., Masouris, Ilias, Kornhuber, Johannes, Ködel, Uwe, Maler, Juan M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5976781/ https://www.ncbi.nlm.nih.gov/pubmed/29881343 http://dx.doi.org/10.3389/fnagi.2018.00152

Ejemplares similares

The Role of Cathepsin B in the Degradation of Aβ and in the Production of Aβ Peptides Starting With Ala2 in Cultured Astrocytes
por: Oberstein, Timo Jan, et al.
Publicado: (2021)

Distributions of Aβ42 and Aβ42/40 in the Cerebrospinal Fluid in View of the Probability Theory
por: Lewczuk, Piotr, et al.
Publicado: (2021)

Combined Analysis of CSF Tau, Aβ42, Aβ1–42% and Aβ1–40(ox)% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia
por: Bibl, Mirko, et al.
Publicado: (2010)

Analysis of Surface Levels of IL-1 Receptors and Macrophage Scavenger Receptor I in Peripheral Immune Cells of Patients With Alzheimer Disease
por: Spitzer, Philipp, et al.
Publicado: (2019)

Amyloid-β levels and cognitive trajectories in non-demented pTau181-positive subjects without amyloidopathy
por: Oberstein, Timo Jan, et al.
Publicado: (2022)

Phagocytosis and LPS alter the maturation state of β-amyloid precursor protein and induce different Aβ peptide release signatures in human mononuclear phagocytes
por: Spitzer, Philipp, et al.
Publicado: (2010)

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
por: Hansson, Oskar, et al.
Publicado: (2019)

Microvesicles from cerebrospinal fluid of patients with Alzheimer’s disease display reduced concentrations of tau and APP protein
por: Spitzer, Philipp, et al.
Publicado: (2019)

Amyloidogenic amyloid-β-peptide variants induce microbial agglutination and exert antimicrobial activity
por: Spitzer, Philipp, et al.
Publicado: (2016)

Reconceptualization of the Erlangen Score for the Assessment of Dementia Risk: The ERlangen Score
por: Utz, Janine, et al.
Publicado: (2023)

Cerebrospinal Fluid Aβ(42/40) Corresponds Better than Aβ(42) to Amyloid PET in Alzheimer’s Disease
por: Lewczuk, Piotr, et al.
Publicado: (2016)

Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease
por: Lewczuk, Piotr, et al.
Publicado: (2018)

CSF nonphosphorylated Tau as a biomarker for the discrimination of AD from CJD
por: Ermann, Natalia, et al.
Publicado: (2018)

Imbalance of Circulating T(h)17 and Regulatory T Cells in Alzheimer’s Disease: A Case Control Study
por: Oberstein, Timo Jan, et al.
Publicado: (2018)

Enteroviral meningitis reduces CSF concentration of Aβ42, but does not affect markers of parenchymal damage
por: Toczylowski, Kacper, et al.
Publicado: (2019)

Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer’s disease
por: Hellwig, Konstantin, et al.
Publicado: (2015)

CSF Aβ42 and Aβ42/Aβ40 Ratio in Alzheimer’s Disease and Frontotemporal Dementias
por: Constantinides, Vasilios C., et al.
Publicado: (2023)

PASSED: Brain atrophy in non-demented individuals in a long-term longitudinal study from two independent cohorts
por: Haas, Anna-Lena, et al.
Publicado: (2023)

CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease
por: Janelidze, Shorena, et al.
Publicado: (2016)

P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status
por: Campbell, Michelle R., et al.
Publicado: (2021)

Pharmacological Inhibition of Amyloidogenic APP Processing and Knock-Down of APP in Primary Human Macrophages Impairs the Secretion of Cytokines
por: Spitzer, Philipp, et al.
Publicado: (2020)

Cerebrospinal Fluid of Patients With Alzheimer’s Disease Contains Increased Percentages of Synaptophysin-Bearing Microvesicles
por: Utz, Janine, et al.
Publicado: (2021)

Predicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40
por: Wisch, Julie K., et al.
Publicado: (2023)

Antemortem CSF Aβ42/Aβ40 ratio predicts Alzheimer's disease pathology better than Aβ42 in rapidly progressive dementias
por: Baiardi, Simone, et al.
Publicado: (2018)

Cellular Receptors of Amyloid β Oligomers (AβOs) in Alzheimer’s Disease
por: Mroczko, Barbara, et al.
Publicado: (2018)

Reduced CSF turnover and decreased ventricular Aβ42 levels are related
por: Serot, Jean-Marie, et al.
Publicado: (2011)

Inhibition of DAMP signaling as an effective adjunctive treatment strategy in pneumococcal meningitis
por: Masouris, Ilias, et al.
Publicado: (2017)

Diagnostic Utility of CSF Tau and Aβ (42) in Dementia: A Meta-Analysis
por: Agarwal, Rachna, et al.
Publicado: (2011)

The Aβ1–42/Aβ1–40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1–42 alone
por: Delaby, Constance, et al.
Publicado: (2022)

CSF protein biomarkers predicting longitudinal reduction of CSF β-amyloid42 in cognitively healthy elders
por: Mattsson, N, et al.
Publicado: (2013)

CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia
por: Bibl, Mirko, et al.
Publicado: (2006)

CSF Potential Biomarkers Aβ42 and Tau: associations of Apo E Genotype
por: Kandimalla, Ramesh, et al.
Publicado: (2010)

Periodontal dysbiosis associates with reduced CSF Aβ42 in cognitively normal elderly
por: Kamer, Angela R., et al.
Publicado: (2021)

Role of purinergic signaling in experimental pneumococcal meningitis
por: Zierhut, Marco, et al.
Publicado: (2017)

CSF sTREM2 in delirium—relation to Alzheimer’s disease CSF biomarkers Aβ42, t-tau and p-tau
por: Henjum, Kristi, et al.
Publicado: (2018)

Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease
por: Parnetti, Lucilla, et al.
Publicado: (2014)

Plasma p‐tau181/Aβ(1‐42) ratio predicts Aβ‐PET status and correlates with CSF‐p‐tau181/Aβ(1‐42) and future cognitive decline
por: Fowler, Christopher J., et al.
Publicado: (2022)

Digit Ratio (2D:4D) Is Not Associated with Alzheimer’s Disease in the Elderly
por: Siegmann, Eva-Maria, et al.
Publicado: (2023)

Interlaboratory proficiency processing scheme in CSF aliquoting: implementation and assessment based on biomarkers of Alzheimer’s disease
por: Lewczuk, Piotr, et al.
Publicado: (2018)

Spot quantification in two dimensional gel electrophoresis image analysis: comparison of different approaches and presentation of a novel compound fitting algorithm
por: Brauner, Jan M, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_2ruvdltegij5vffm1rrh8vf6h8